{
    "doc_id": "v1_data/DeepSeek-R1_gpqa-diamond_responses_106.json",
    "metadata": {
        "model_id": "deepseek-ai/DeepSeek-R1",
        "correct_answer": "B"
    },
    "raw_text": {
        "question": "Imagine a situation where a novel natural molecule, Xantheraquin, is discovered and is being investigated for in silico testing against a bacterial pathogen that is multidrug resistant. Preliminary studies indicate that Xantheraquin has multiple chiral centers and can exist in various tautomeric forms. Which of the following steps would be the MOST crucial before proceeding with in silico docking studies, given the complexities of bioinformatics in structure-based drug discovery, ?\nA. Focus on Xantheraquin's pharmacokinetics and ADME (Absorption, Distribution, Metabolism, Excretion) properties, using molecular dynamics simulations to predict its behavior in a biological system.\nB. Combine in silico predictions with preliminary in vitro binding affinity assays to validate the most promising forms of Xantheraquin before extensive docking studies.\nC. Analyze all tautomeric and chiral forms, but prioritize those forms that are most likely to be biologically active based on physicochemical properties.\nD. Use the most stable chiral form of Xantheraquin, relying on quantum mechanical calculations to predict its interaction with the bacterial target.",
        "response": "Okay, let's tackle this question step by step. So, the scenario is about a new molecule called Xantheraquin that's being studied for in silico testing against a multidrug-resistant bacterial pathogen. The key points here are that Xantheraquin has multiple chiral centers and can exist in various tautomeric forms. The question is asking which step is most crucial before proceeding with in silico docking studies, considering the complexities in bioinformatics and structure-based drug discovery.\n\nFirst, I need to recall what in silico docking studies involve. These studies typically use computer models to predict how a drug molecule (ligand) interacts with a target protein. The accuracy of these predictions depends heavily on having the correct 3D structure of the ligand. Since Xantheraquin has multiple chiral centers and tautomeric forms, this introduces variability in its possible structures. Chiral centers mean different stereoisomers (enantiomers, diastereomers) exist, and tautomerism refers to different structural isomers that can interconvert by the movement of a proton and a double bond. Each of these forms could have different binding affinities to the target.\n\nNow, looking at the options:\n\nA. Focus on pharmacokinetics and ADME using molecular dynamics. While ADME properties are important in drug development, the question is about the step before docking studies. Pharmacokinetics is more about how the body affects the drug, which might come later after establishing binding potential. So maybe not the most crucial first step here.\n\nB. Combine in silico predictions with in vitro assays. This seems like a validation step. But the question is about what's crucial before proceeding with the docking studies themselves. If you do in vitro assays first, that's mixing wet lab with dry lab. But the question is about steps before the in silico docking. So maybe B is about validating after some initial predictions, but the question is about what's needed before proceeding with the docking.\n\nC. Analyze all tautomeric and chiral forms but prioritize based on physicochemical properties. This sounds like considering the possible structural variations and selecting the most likely active forms. Since different tautomers and enantiomers can have different activities, it's important to consider which ones are more probable. Physicochemical properties like stability, solubility, etc., might indicate which forms are biologically relevant. So this step would narrow down the structures to use in docking, making the study feasible and more accurate.\n\nD. Use the most stable chiral form via quantum calculations. While stability is a factor, the most stable form might not be the biologically active one. For example, in some cases, the less stable form might bind better. Also, tautomerism isn't addressed here\u2014only chiral centers. So this might miss important active tautomers.\n\nSo, the key issue is that Xantheraquin has multiple forms. Docking studies require a specific 3D structure. If you don't account for all possible active forms, you might miss the actual binding form. However, analyzing all possible forms could be computationally expensive. Therefore, prioritizing the most likely ones based on physicochemical properties (like stability, bioavailability, etc.) would be crucial. That's option C. Option D only considers chiral forms and stability, not tautomers. Option B involves in vitro assays, which might not be done yet. Option A is about ADME, which is important but not the immediate step before docking. So the answer is C."
    },
    "nodes": [
        {
            "id": "ctx0",
            "annotation": false,
            "start": 0,
            "end": 186,
            "label": "context",
            "text": "Imagine a situation where a novel natural molecule, Xantheraquin, is discovered and is being investigated for in silico testing against a bacterial pathogen that is multidrug resistant. ",
            "source": "question"
        },
        {
            "id": "ctx1",
            "annotation": false,
            "start": 186,
            "end": 304,
            "label": "context",
            "text": "Preliminary studies indicate that Xantheraquin has multiple chiral centers and can exist in various tautomeric forms. ",
            "source": "question"
        },
        {
            "id": "ctx2",
            "annotation": false,
            "start": 304,
            "end": 487,
            "label": "context",
            "text": "Which of the following steps would be the MOST crucial before proceeding with in silico docking studies, given the complexities of bioinformatics in structure-based drug discovery, ?\n",
            "source": "question"
        },
        {
            "id": "ctx3",
            "annotation": false,
            "start": 487,
            "end": 490,
            "label": "context",
            "text": "A. ",
            "source": "question"
        },
        {
            "id": "ctx4",
            "annotation": false,
            "start": 490,
            "end": 687,
            "label": "context",
            "text": "Focus on Xantheraquin's pharmacokinetics and ADME (Absorption, Distribution, Metabolism, Excretion) properties, using molecular dynamics simulations to predict its behavior in a biological system.\n",
            "source": "question"
        },
        {
            "id": "ctx5",
            "annotation": false,
            "start": 687,
            "end": 690,
            "label": "context",
            "text": "B. ",
            "source": "question"
        },
        {
            "id": "ctx6",
            "annotation": false,
            "start": 690,
            "end": 857,
            "label": "context",
            "text": "Combine in silico predictions with preliminary in vitro binding affinity assays to validate the most promising forms of Xantheraquin before extensive docking studies.\n",
            "source": "question"
        },
        {
            "id": "ctx7",
            "annotation": false,
            "start": 857,
            "end": 1012,
            "label": "context",
            "text": "C. Analyze all tautomeric and chiral forms, but prioritize those forms that are most likely to be biologically active based on physicochemical properties.\n",
            "source": "question"
        },
        {
            "id": "ctx8",
            "annotation": false,
            "start": 1012,
            "end": 1160,
            "label": "context",
            "text": "D. Use the most stable chiral form of Xantheraquin, relying on quantum mechanical calculations to predict its interaction with the bacterial target.",
            "source": "question"
        },
        {
            "id": "resp0",
            "annotation": false,
            "start": 0,
            "end": 47,
            "label": "planning",
            "text": "Okay, let's tackle this question step by step. ",
            "source": "response"
        },
        {
            "id": "resp1",
            "annotation": false,
            "start": 47,
            "end": 201,
            "label": "restatement",
            "text": "So, the scenario is about a new molecule called Xantheraquin that's being studied for in silico testing against a multidrug-resistant bacterial pathogen. ",
            "source": "response"
        },
        {
            "id": "resp2",
            "annotation": false,
            "start": 201,
            "end": 314,
            "label": "fact",
            "text": "The key points here are that Xantheraquin has multiple chiral centers and can exist in various tautomeric forms. ",
            "source": "response"
        },
        {
            "id": "resp3",
            "annotation": false,
            "start": 314,
            "end": 498,
            "label": "planning",
            "text": "The question is asking which step is most crucial before proceeding with in silico docking studies, considering the complexities in bioinformatics and structure-based drug discovery.\n\n",
            "source": "response"
        },
        {
            "id": "resp4",
            "annotation": false,
            "start": 498,
            "end": 562,
            "label": "planning",
            "text": "First, I need to recall what in silico docking studies involve. ",
            "source": "response"
        },
        {
            "id": "resp5",
            "annotation": false,
            "start": 562,
            "end": 679,
            "label": "fact",
            "text": "These studies typically use computer models to predict how a drug molecule (ligand) interacts with a target protein. ",
            "source": "response"
        },
        {
            "id": "resp6",
            "annotation": false,
            "start": 679,
            "end": 779,
            "label": "fact",
            "text": "The accuracy of these predictions depends heavily on having the correct 3D structure of the ligand. ",
            "source": "response"
        },
        {
            "id": "resp7",
            "annotation": false,
            "start": 779,
            "end": 904,
            "label": "reasoning",
            "text": "Since Xantheraquin has multiple chiral centers and tautomeric forms, this introduces variability in its possible structures. ",
            "source": "response"
        },
        {
            "id": "resp8",
            "annotation": false,
            "start": 904,
            "end": 1108,
            "label": "fact",
            "text": "Chiral centers mean different stereoisomers (enantiomers, diastereomers) exist, and tautomerism refers to different structural isomers that can interconvert by the movement of a proton and a double bond. ",
            "source": "response"
        },
        {
            "id": "resp9",
            "annotation": false,
            "start": 1108,
            "end": 1184,
            "label": "reasoning",
            "text": "Each of these forms could have different binding affinities to the target.\n\n",
            "source": "response"
        },
        {
            "id": "resp10",
            "annotation": false,
            "start": 1184,
            "end": 1214,
            "label": "planning",
            "text": "Now, looking at the options:\n\n",
            "source": "response"
        },
        {
            "id": "resp11",
            "annotation": false,
            "start": 1214,
            "end": 1278,
            "label": "restatement",
            "text": "A. Focus on pharmacokinetics and ADME using molecular dynamics. ",
            "source": "response"
        },
        {
            "id": "resp12",
            "annotation": false,
            "start": 1278,
            "end": 1390,
            "label": "reasoning",
            "text": "While ADME properties are important in drug development, the question is about the step before docking studies. ",
            "source": "response"
        },
        {
            "id": "resp13",
            "annotation": false,
            "start": 1390,
            "end": 1513,
            "label": "reasoning",
            "text": "Pharmacokinetics is more about how the body affects the drug, which might come later after establishing binding potential. ",
            "source": "response"
        },
        {
            "id": "resp14",
            "annotation": false,
            "start": 1513,
            "end": 1561,
            "label": "reasoning",
            "text": "So maybe not the most crucial first step here.\n\n",
            "source": "response"
        },
        {
            "id": "resp15",
            "annotation": false,
            "start": 1561,
            "end": 1616,
            "label": "restatement",
            "text": "B. Combine in silico predictions with in vitro assays. ",
            "source": "response"
        },
        {
            "id": "resp16",
            "annotation": false,
            "start": 1616,
            "end": 1651,
            "label": "reasoning",
            "text": "This seems like a validation step. ",
            "source": "response"
        },
        {
            "id": "resp17",
            "annotation": false,
            "start": 1651,
            "end": 1747,
            "label": "reasoning",
            "text": "But the question is about what's crucial before proceeding with the docking studies themselves. ",
            "source": "response"
        },
        {
            "id": "resp18",
            "annotation": false,
            "start": 1747,
            "end": 1816,
            "label": "reasoning",
            "text": "If you do in vitro assays first, that's mixing wet lab with dry lab. ",
            "source": "response"
        },
        {
            "id": "resp19",
            "annotation": false,
            "start": 1816,
            "end": 1878,
            "label": "reasoning",
            "text": "But the question is about steps before the in silico docking. ",
            "source": "response"
        },
        {
            "id": "resp20",
            "annotation": false,
            "start": 1878,
            "end": 2018,
            "label": "reasoning",
            "text": "So maybe B is about validating after some initial predictions, but the question is about what's needed before proceeding with the docking.\n\n",
            "source": "response"
        },
        {
            "id": "resp21",
            "annotation": false,
            "start": 2018,
            "end": 2113,
            "label": "restatement",
            "text": "C. Analyze all tautomeric and chiral forms but prioritize based on physicochemical properties. ",
            "source": "response"
        },
        {
            "id": "resp22",
            "annotation": false,
            "start": 2113,
            "end": 2221,
            "label": "reasoning",
            "text": "This sounds like considering the possible structural variations and selecting the most likely active forms. ",
            "source": "response"
        },
        {
            "id": "resp23",
            "annotation": false,
            "start": 2221,
            "end": 2351,
            "label": "reasoning",
            "text": "Since different tautomers and enantiomers can have different activities, it's important to consider which ones are more probable. ",
            "source": "response"
        },
        {
            "id": "resp24",
            "annotation": false,
            "start": 2351,
            "end": 2466,
            "label": "fact",
            "text": "Physicochemical properties like stability, solubility, etc., might indicate which forms are biologically relevant. ",
            "source": "response"
        },
        {
            "id": "resp25",
            "annotation": false,
            "start": 2466,
            "end": 2577,
            "label": "reasoning",
            "text": "So this step would narrow down the structures to use in docking, making the study feasible and more accurate.\n\n",
            "source": "response"
        },
        {
            "id": "resp26",
            "annotation": false,
            "start": 2577,
            "end": 2638,
            "label": "restatement",
            "text": "D. Use the most stable chiral form via quantum calculations. ",
            "source": "response"
        },
        {
            "id": "resp27",
            "annotation": false,
            "start": 2638,
            "end": 2730,
            "label": "reasoning",
            "text": "While stability is a factor, the most stable form might not be the biologically active one. ",
            "source": "response"
        },
        {
            "id": "resp28",
            "annotation": false,
            "start": 2730,
            "end": 2798,
            "label": "reasoning",
            "text": "For example, in some cases, the less stable form might bind better. ",
            "source": "response"
        },
        {
            "id": "resp29",
            "annotation": false,
            "start": 2798,
            "end": 2858,
            "label": "reasoning",
            "text": "Also, tautomerism isn't addressed here\u2014only chiral centers. ",
            "source": "response"
        },
        {
            "id": "resp30",
            "annotation": false,
            "start": 2858,
            "end": 2906,
            "label": "reasoning",
            "text": "So this might miss important active tautomers.\n\n",
            "source": "response"
        },
        {
            "id": "resp31",
            "annotation": false,
            "start": 2906,
            "end": 2965,
            "label": "restatement",
            "text": "So, the key issue is that Xantheraquin has multiple forms. ",
            "source": "response"
        },
        {
            "id": "resp32",
            "annotation": false,
            "start": 2965,
            "end": 3014,
            "label": "fact",
            "text": "Docking studies require a specific 3D structure. ",
            "source": "response"
        },
        {
            "id": "resp33",
            "annotation": false,
            "start": 3014,
            "end": 3106,
            "label": "reasoning",
            "text": "If you don't account for all possible active forms, you might miss the actual binding form. ",
            "source": "response"
        },
        {
            "id": "resp34",
            "annotation": false,
            "start": 3106,
            "end": 3180,
            "label": "reasoning",
            "text": "However, analyzing all possible forms could be computationally expensive. ",
            "source": "response"
        },
        {
            "id": "resp35",
            "annotation": false,
            "start": 3180,
            "end": 3319,
            "label": "reasoning",
            "text": "Therefore, prioritizing the most likely ones based on physicochemical properties (like stability, bioavailability, etc.) would be crucial. ",
            "source": "response"
        },
        {
            "id": "resp36",
            "annotation": false,
            "start": 3319,
            "end": 3336,
            "label": "reasoning",
            "text": "That's option C. ",
            "source": "response"
        },
        {
            "id": "resp37",
            "annotation": false,
            "start": 3336,
            "end": 3403,
            "label": "reasoning",
            "text": "Option D only considers chiral forms and stability, not tautomers. ",
            "source": "response"
        },
        {
            "id": "resp38",
            "annotation": false,
            "start": 3403,
            "end": 3467,
            "label": "reasoning",
            "text": "Option B involves in vitro assays, which might not be done yet. ",
            "source": "response"
        },
        {
            "id": "resp39",
            "annotation": false,
            "start": 3467,
            "end": 3553,
            "label": "reasoning",
            "text": "Option A is about ADME, which is important but not the immediate step before docking. ",
            "source": "response"
        },
        {
            "id": "resp40",
            "annotation": false,
            "start": 3553,
            "end": 3572,
            "label": "conclusion",
            "text": "So the answer is C.",
            "source": "response"
        }
    ],
    "edges": [
        {
            "id": "e0",
            "from_node_id": "ctx2",
            "to_node_id": "resp0",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e1",
            "from_node_id": "ctx0",
            "to_node_id": "resp1",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e2",
            "from_node_id": "resp1",
            "to_node_id": "resp2",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e3",
            "from_node_id": "resp0",
            "to_node_id": "resp3",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e4",
            "from_node_id": "resp2",
            "to_node_id": "resp3",
            "label": "plan:frontier-plan"
        },
        {
            "id": "e5",
            "from_node_id": "resp3",
            "to_node_id": "resp4",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e6",
            "from_node_id": "resp1",
            "to_node_id": "resp5",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e7",
            "from_node_id": "resp4",
            "to_node_id": "resp5",
            "label": "reason:plan-step"
        },
        {
            "id": "e8",
            "from_node_id": "resp4",
            "to_node_id": "resp6",
            "label": "reason:plan-step"
        },
        {
            "id": "e9",
            "from_node_id": "resp5",
            "to_node_id": "resp6",
            "label": "reason:fact-detail"
        },
        {
            "id": "e10",
            "from_node_id": "resp2",
            "to_node_id": "resp7",
            "label": "reason:fact-detail"
        },
        {
            "id": "e11",
            "from_node_id": "resp6",
            "to_node_id": "resp7",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e12",
            "from_node_id": "resp7",
            "to_node_id": "resp8",
            "label": "reason:fact-detail"
        },
        {
            "id": "e13",
            "from_node_id": "resp7",
            "to_node_id": "resp9",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e14",
            "from_node_id": "resp8",
            "to_node_id": "resp9",
            "label": "reason:fact-detail"
        },
        {
            "id": "e15",
            "from_node_id": "resp3",
            "to_node_id": "resp10",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e16",
            "from_node_id": "resp9",
            "to_node_id": "resp10",
            "label": "plan:plan-subplan"
        },
        {
            "id": "e17",
            "from_node_id": "ctx4",
            "to_node_id": "resp11",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e18",
            "from_node_id": "resp10",
            "to_node_id": "resp11",
            "label": "reason:plan-step"
        },
        {
            "id": "e19",
            "from_node_id": "resp10",
            "to_node_id": "resp12",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e20",
            "from_node_id": "resp11",
            "to_node_id": "resp12",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e21",
            "from_node_id": "resp11",
            "to_node_id": "resp13",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e22",
            "from_node_id": "resp12",
            "to_node_id": "resp13",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e23",
            "from_node_id": "resp12",
            "to_node_id": "resp14",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e24",
            "from_node_id": "resp13",
            "to_node_id": "resp14",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e25",
            "from_node_id": "ctx6",
            "to_node_id": "resp15",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e26",
            "from_node_id": "resp10",
            "to_node_id": "resp15",
            "label": "reason:plan-step"
        },
        {
            "id": "e27",
            "from_node_id": "resp12",
            "to_node_id": "resp16",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e28",
            "from_node_id": "resp13",
            "to_node_id": "resp16",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e29",
            "from_node_id": "resp14",
            "to_node_id": "resp16",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e30",
            "from_node_id": "resp15",
            "to_node_id": "resp16",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e31",
            "from_node_id": "resp10",
            "to_node_id": "resp17",
            "label": "reason:plan-step"
        },
        {
            "id": "e32",
            "from_node_id": "resp12",
            "to_node_id": "resp17",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e33",
            "from_node_id": "resp13",
            "to_node_id": "resp17",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e34",
            "from_node_id": "resp14",
            "to_node_id": "resp17",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e35",
            "from_node_id": "resp16",
            "to_node_id": "resp17",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e36",
            "from_node_id": "resp16",
            "to_node_id": "resp18",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e37",
            "from_node_id": "resp17",
            "to_node_id": "resp18",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e38",
            "from_node_id": "resp17",
            "to_node_id": "resp19",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e39",
            "from_node_id": "resp18",
            "to_node_id": "resp19",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e40",
            "from_node_id": "resp15",
            "to_node_id": "resp20",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e41",
            "from_node_id": "resp16",
            "to_node_id": "resp20",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e42",
            "from_node_id": "resp17",
            "to_node_id": "resp20",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e43",
            "from_node_id": "resp18",
            "to_node_id": "resp20",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e44",
            "from_node_id": "resp19",
            "to_node_id": "resp20",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e45",
            "from_node_id": "ctx7",
            "to_node_id": "resp21",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e46",
            "from_node_id": "resp10",
            "to_node_id": "resp21",
            "label": "reason:plan-step"
        },
        {
            "id": "e47",
            "from_node_id": "resp20",
            "to_node_id": "resp21",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e48",
            "from_node_id": "resp21",
            "to_node_id": "resp22",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e49",
            "from_node_id": "resp21",
            "to_node_id": "resp23",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e50",
            "from_node_id": "resp22",
            "to_node_id": "resp23",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e51",
            "from_node_id": "resp23",
            "to_node_id": "resp24",
            "label": "reason:fact-detail"
        },
        {
            "id": "e52",
            "from_node_id": "resp21",
            "to_node_id": "resp25",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e53",
            "from_node_id": "resp22",
            "to_node_id": "resp25",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e54",
            "from_node_id": "resp23",
            "to_node_id": "resp25",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e55",
            "from_node_id": "resp24",
            "to_node_id": "resp25",
            "label": "reason:fact-detail"
        },
        {
            "id": "e56",
            "from_node_id": "ctx8",
            "to_node_id": "resp26",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e57",
            "from_node_id": "resp10",
            "to_node_id": "resp26",
            "label": "reason:plan-step"
        },
        {
            "id": "e58",
            "from_node_id": "resp23",
            "to_node_id": "resp27",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e59",
            "from_node_id": "resp24",
            "to_node_id": "resp27",
            "label": "reason:fact-detail"
        },
        {
            "id": "e60",
            "from_node_id": "resp26",
            "to_node_id": "resp27",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e61",
            "from_node_id": "resp23",
            "to_node_id": "resp28",
            "label": "evaluate:support"
        },
        {
            "id": "e62",
            "from_node_id": "resp27",
            "to_node_id": "resp28",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e63",
            "from_node_id": "resp21",
            "to_node_id": "resp29",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e64",
            "from_node_id": "resp22",
            "to_node_id": "resp29",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e65",
            "from_node_id": "resp23",
            "to_node_id": "resp29",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e66",
            "from_node_id": "resp24",
            "to_node_id": "resp29",
            "label": "reason:fact-detail"
        },
        {
            "id": "e67",
            "from_node_id": "resp25",
            "to_node_id": "resp29",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e68",
            "from_node_id": "resp26",
            "to_node_id": "resp29",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e69",
            "from_node_id": "resp27",
            "to_node_id": "resp29",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e70",
            "from_node_id": "resp28",
            "to_node_id": "resp29",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e71",
            "from_node_id": "resp27",
            "to_node_id": "resp30",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e72",
            "from_node_id": "resp28",
            "to_node_id": "resp30",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e73",
            "from_node_id": "resp29",
            "to_node_id": "resp30",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e74",
            "from_node_id": "resp2",
            "to_node_id": "resp31",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e75",
            "from_node_id": "resp7",
            "to_node_id": "resp31",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e76",
            "from_node_id": "resp8",
            "to_node_id": "resp31",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e77",
            "from_node_id": "resp9",
            "to_node_id": "resp31",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e78",
            "from_node_id": "resp6",
            "to_node_id": "resp32",
            "label": "reason:fact-detail"
        },
        {
            "id": "e79",
            "from_node_id": "resp31",
            "to_node_id": "resp32",
            "label": "reason:fact-detail"
        },
        {
            "id": "e80",
            "from_node_id": "resp23",
            "to_node_id": "resp33",
            "label": "evaluate:support"
        },
        {
            "id": "e81",
            "from_node_id": "resp25",
            "to_node_id": "resp33",
            "label": "evaluate:support"
        },
        {
            "id": "e82",
            "from_node_id": "resp31",
            "to_node_id": "resp33",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e83",
            "from_node_id": "resp32",
            "to_node_id": "resp33",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e84",
            "from_node_id": "resp21",
            "to_node_id": "resp34",
            "label": "reason:plan-step"
        },
        {
            "id": "e85",
            "from_node_id": "resp22",
            "to_node_id": "resp34",
            "label": "reason:plan-step"
        },
        {
            "id": "e86",
            "from_node_id": "resp24",
            "to_node_id": "resp34",
            "label": "reason:fact-detail"
        },
        {
            "id": "e87",
            "from_node_id": "resp31",
            "to_node_id": "resp34",
            "label": "reason:fact-detail"
        },
        {
            "id": "e88",
            "from_node_id": "resp33",
            "to_node_id": "resp34",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e89",
            "from_node_id": "resp24",
            "to_node_id": "resp35",
            "label": "reason:fact-detail"
        },
        {
            "id": "e90",
            "from_node_id": "resp25",
            "to_node_id": "resp35",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e91",
            "from_node_id": "resp34",
            "to_node_id": "resp35",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e92",
            "from_node_id": "resp21",
            "to_node_id": "resp36",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e93",
            "from_node_id": "resp35",
            "to_node_id": "resp36",
            "label": "evaluate:support"
        },
        {
            "id": "e94",
            "from_node_id": "resp29",
            "to_node_id": "resp37",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e95",
            "from_node_id": "resp30",
            "to_node_id": "resp37",
            "label": "evaluate:support"
        },
        {
            "id": "e96",
            "from_node_id": "resp16",
            "to_node_id": "resp38",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e97",
            "from_node_id": "resp17",
            "to_node_id": "resp38",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e98",
            "from_node_id": "resp18",
            "to_node_id": "resp38",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e99",
            "from_node_id": "resp19",
            "to_node_id": "resp38",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e100",
            "from_node_id": "resp20",
            "to_node_id": "resp38",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e101",
            "from_node_id": "resp11",
            "to_node_id": "resp39",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e102",
            "from_node_id": "resp12",
            "to_node_id": "resp39",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e103",
            "from_node_id": "resp13",
            "to_node_id": "resp39",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e104",
            "from_node_id": "resp14",
            "to_node_id": "resp39",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e105",
            "from_node_id": "resp35",
            "to_node_id": "resp40",
            "label": "reason:premise-conclusion"
        },
        {
            "id": "e106",
            "from_node_id": "resp36",
            "to_node_id": "resp40",
            "label": "reason:stmt-restatement"
        },
        {
            "id": "e107",
            "from_node_id": "resp37",
            "to_node_id": "resp40",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e108",
            "from_node_id": "resp38",
            "to_node_id": "resp40",
            "label": "reason:stmt-correction"
        },
        {
            "id": "e109",
            "from_node_id": "resp39",
            "to_node_id": "resp40",
            "label": "reason:stmt-correction"
        }
    ]
}